Centessa Pharmaceuticals plc Nam.-Akt.(Sp.ADRs)/1 o.N.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
197.39%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.29 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 34 G | 0 Units |
| PRICE DETERMINATION TIME | 06/04/2026 / 11:02:12 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 34 | 33.8 |
| PREV. DAY'S PRICE | 34.2 | (06/03) |
| CHANGE DAY BEFORE | -0.20 | -0.58 % |
| 52 WEEK HIGH / LOW | 34.8 (03/31) | 10.1 (06/09) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | -1.48 | -1.42 | -1.29 | -1.90 | -1.46 |
| DIVIDENDS PER SHARE | - | - | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | - | - | - | - | - |
| PRICE - BOOK RATIO | - | - | 7.08 | 5.53 | 3.33 |
| PRICE - SALES RATIO | - | - | 225.76 | - | 111.28 |
| PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3CQ72 |
| ISIN | US1523091007 |
| SYMBOL | 260 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | CENTESSA PHARMACEUTICALS |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.59 % | 2.40 % | 51.33 % | 41.32 % | 197.39 % | 734.15 % | 71.86 % | 64.42 % |
| HIGH | 34.20 | 34.20 | 34.80 | 34.80 | 34.80 | 34.80 | 34.80 | 34.80 |
| LOW | 33.60 | 33.00 | 21.00 | 18.30 | 10.10 | 4.06 | 2.82 | 18.30 |
Dividend
per share
CENTESSA PHARMACEUTICALS does not deliver dividend information
Company profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.